Navigation Links
Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
Date:10/4/2011

DURHAM, N.C., Oct. 4, 2011 /PRNewswire/ -- Argos Therapeutics, Inc. today announced that its late scientific co-founder and scientific advisor Ralph M. Steinman, M.D., was awarded the Nobel Prize in medicine for the discovery of dendritic cells as critical sentinels of the immune system.

Dr. Steinman's discovery of dendritic cells and his research of dendritic cell biology and the role of dendritic cells in adaptive immunity have led to the development of Argos' core technology, Arcelis. 

"The Nobel Prize is further validation of the lifelong work of Dr. Steinman and Argos looks forward to continuing his work through further development of its dendritic cell-based immunotherapies," said Charles Nicolette, Ph.D., Argos' chief scientific officer and vice president of research and development. "We are planning to advance our Arcelis immunotherapy for the treatment of metastatic renal cell carcinoma, AGS-003, into a global Phase 3 clinical trial."

Dr. Nicolette added, "We extend our deepest condolences to Dr. Steinman's family for his untimely passing."

Dr. Steinman was a Henry G. Kunkel Professor at The Rockefeller University and a senior physician at The Rockefeller University Hospital. His research focused on the immune system including the human immune system in the setting of several diseases. His research aimed at developing vaccines and immune-based therapies for tumors, infections and autoimmune diseases.  Dr. Steinman received a B.S. degree from McGill University and an M.D. from Harvard University.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune respons
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
2. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
3. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
4. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
5. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
6. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
7. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
8. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
9. Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
11. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... ® Complete Knee System. ... th year since Zimmer first introduced the NexGen knee ... date, more than five million implantations of the NexGen knee ... the NexGen knee demonstrates the importance of design innovation and ...
(Date:3/27/2015)... March 27, 2015 Report Details  ... leading ophthalmic drug companies  What does the ... ophthalmic industry ? Visiongain,s brand new report shows you ... prospects there. Our 242-page report provides 185 ... in the industry and the future market prospects. Our ...
(Date:3/27/2015)... The International Myeloma Foundation (IMF) – improving ... toward prevention and a cure – today commended Representative ... resolution (H. Res. 174) that supports the designation of ... Awareness Month." Currently there are more than ... 110,000 new cases are diagnosed yearly, according to the ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... Calif., Dec. 9, 2010 Ambry Genetics, a global ... sciences industries, announced today that it has officially launched ... Genetics has been an early adapter of Illumina sequencing ... Certified Service Provider. (Logo:   http://photos.prnewswire.com/prnh/20090428/LA06744LOGO ...
... 9, 2010 A new study shows that ... hormonal therapy tamoxifen in patients with hormone-receptor positive/human ... cancer who have been previously treated with an ... tamoxifen alone. These results were presented today at ...
Cached Medicine Technology:Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 3Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 4Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 5Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 6Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 7Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 8Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 9Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 10Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 11
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with ... provider for the 2015 and 2016 season. As the Storm’s ... an athletic trainer for the team throughout each season. Tonight, ... the Cleveland Gladiators at Amalie Arena; the game starts at ... us as it gives us the opportunity, to provide health ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
(Date:3/27/2015)... 2015 On February 21, 2015, ... the Stardust Penthouse on the rooftop of the ... leading sustainable product TV and film placement producer, ... event, which featured some of the world’s top ... and services. , “We were honored to have ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
Breaking Medicine News(10 mins):Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... ... new limited partner to its first venture fund, bolstering the fund’s ability to invest ... ... Bay Capital, LLC, has added a new limited partner to its first venture fund, ...
... ... to give the keynote speech at the Affiliate Summit 2010 event in NYC , ... (PRWEB) February 24, 2010 -- Twice ... and network about how to create and promote a successful online business. This year Jim ...
... , ... Unfortunately over the years, lawsuits and related investigations suggest some health plans have ... simply missing checkboxes on complex insurance forms. However, consumers seeking to appeal their ... appeal. , ...
... ... Services Providers. , ... Renton, WA (PRWEB) February 24, 2010 -- Parallels , worldwide leader in Cloud ... offerings for Apple environments with the introduction of the world’s first bare metal hypervisor ...
... ... small business. , ... (PRWEB) February 24, 2010 -- Verndale, a leading mid-market web technology and consultancy firm ... business, which is redefining the way websites are designed and managed. With Jumpstart, clients ...
... uninsured children, report says , WEDNESDAY, Feb. 24 (HealthDay ... of uninsured children with asthma by 75 percent by ... insurance programs and expanding eligibility, a new report suggests. ... care for kids with asthma costs an average of ...
Cached Medicine News:Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 2Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 3Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 4Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 2Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 2Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 4Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 2Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 3Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 4Health News:Verndale Announces the Release of Jumpstart 2Health News:Verndale Announces the Release of Jumpstart 3Health News:Existing Health Programs Could Help More Kids With Asthma 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: